Stockscreener 앱 받기
16.76
2.51%
0.41
Moonlake Immunotherapeutics 주식(MLTX)의 최신 뉴스
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns - Investing.com Canada
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs - TipRanks
MACD Signal: Is MoonLake Immunotherapeutics stock suitable for long term investingTrade Risk Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Stop Loss: Is IGMS benefiting from interest rate changes2025 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Exit Recap: Will MoonLake Immunotherapeutics stock continue upward momentumOil Prices & Safe Capital Growth Stock Tips - moha.gov.vn
Death Cross: How is MoonLake Immunotherapeutics managing supply chain issues2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Buyback Watch: What is the Moat Score of MoonLake ImmunotherapeuticsMarket Sentiment Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
Guidance Update: Why MoonLake Immunotherapeutics stock could rally in 2025Take Profit & AI Powered Market Trend Analysis - Bộ Nội Vụ
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - Stocktwits
Published on: 2026-01-13 06:01:31 - Улправда
(MLTX) Risk Channels and Responsive Allocation - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations - MSN
Why MoonLake Immunotherapeutics (MLTX) Is Up 54.7% After FDA Opens Path to HS BLA Filing - simplywall.st
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
BTIG Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $45 - 富途牛牛
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 9.6%Time to Buy? - MarketBeat
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC Wainwright - MarketBeat
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (MLTX) Is Up 20.0% After FDA Clears Existing SLK Data For HS BLA Path - Yahoo Finance
What margin trends mean for MoonLake Immunotherapeutics stockQuarterly Trade Review & High Conviction Investment Ideas - ulpravda.ru
Will MoonLake Immunotherapeutics stock reach all time highs in 2025CEO Change & Growth Focused Entry Reports - ulpravda.ru
Will MoonLake Immunotherapeutics stock benefit from sector rotationWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
MoonLake Immunotherapeutics Stock Collapses. Why It’s Down 88%. - MSN
Biopharma bites: A flurry of financings headlined by Diagonal, plus updates from Servier, MoonLake - FirstWord
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials - TechStock²
Will MoonLake Immunotherapeutics stock rally after Fed decisionsMarket Sentiment Report & Consistent Profit Trading Strategies - ulpravda.ru
Why MoonLake Immunotherapeutics stock could rally in 20252025 Top Gainers & Safe Investment Capital Preservation Plans - ulpravda.ru
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating - TipRanks
MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug - Investor's Business Daily
MoonLake soars 45% after FDA clears path for key skin drug | Tap to know more | Inshorts - Inshorts
MLTX Surge: Will The Momentum Last? - StocksToTrade
What is the fair value of MoonLake Immunotherapeutics stock nowMarket Growth Review & Technical Entry and Exit Tips - ulpravda.ru
MoonLake States FDA Might Permit Skin Medication Submission Without Additional Studies, Shares Surge - bitget.com
Why Did MLTX Stock Jump 45% In Pre-Market Today? - Stocktwits
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - Benzinga
4.73%
0.92%
자본화:
|
볼륨(24시간):